Mr. Jeffrey D. Capello is Chief Financial Officer, Executive Vice President of Boston Scientific Corporationrationration, since March 1, 2010. Before then, he served as Senior Vice President and Chief Accounting Officer since June 2008 when he joined Boston Scientific. Prior to joining, he was Senior Vice President and Chief Financial Officer with responsibilities for Business Development at PerkinElmer, Inc. from 2006 to 2008. Prior to that, he was PerkinElmer?s Vice President of Finance, Corporationrationrate Controller and Treasurer from 2002 to 2006 and the Vice President, Finance, Corporationrationrate Controller, Chief Accounting Officer and Treasurer from 2001 to 2005. From 1991 to June 2001, he held positions including that of partner from 1997 to 2001 at PriceWaterhouseCoopers LLP, a public accounting firm, initially in the United States and later in the Netherlands. Mr. Capello served on the Board of Directors of Sirtis Pharmaceuticals, Inc. including its Audit Committee as both a member and its chair. He holds a B.S. degree in business administration from the University of Vermont and a M.B.A. degree from the Harvard Business School. Mr. Capello is a certified public accountant.
The company has Return on Asset of 3.1 % which means that on every $100 spent on asset it made $3.1 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of (50.67) % meaning that it generated no profit with money invested by stockholders.
The company has 4.25 B in debt with debt to equity (D/E) ratio of 0.65 which is OK given its current industry classification. Boston Scientific Corporation has Current Ratio of 1.86 which is typical for the industry and considered as normal.
Boston Scientific Corporationration develops, manufactures, and markets medical devices used in various interventional medical specialties worldwide. Boston Scientific Corporation [BSX] is traded on New York Stock Exchange in USA. It is located in Natick, MA and employs 24,000 people. Filter other
Click "OK" to permanently delete this portfolio. Click "Cancel" if you have changed your mind.
Report was successfully generated.
You can either (1) right-mouth click the image to download it to your local drive or simply (2) copy and paste the
image data below to include picture of this graph on your web page without downloading the image file
Copy and paste above text right to your web page html
Macroaxis is user-driven community of investors. We appreciate any feedback or comment you can provide.
Please fill out our quick survey to help us provide your with a better service and user experience
Most of the functionality on our site is free to use.
However we do provide premium service to sophisticated investors. Our premium subscription will give you unprecedented
capabilities to optimize your portfolios using robust financial analysis toolkit, fast mean-variance optimization engine, and proven portfolio theory
NYSE Boston Scientific Corporation
-0.29%
Equity Search
Advanced Search
Market Screener
Adviser Directory
Suggest Portfolio
Backtest Watchlist
Analyze Correlations
View Transactions
Check Volatility
Import Equities
Advice
